Stryker Corporation (SYK.NYSE) AI FORECASTS & ADVISOR ANALYSIS

The physics of the operating room are fundamentally rewritten as Stryker accelerates the integration of agentic AI. Mako achieves FDA clearance for autonomous sub-routines, tripling surgical throughput.

• Software recurring revenue explodes, pushing operating margins toward 25%+.
• The 'OS for the OR' narrative goes mainstream, rerating the multiple from 37x to 45x.
• Demographic tailwinds violently accelerate as active lifespans increase.
• Market capitalization easily scales past $250B as Stryker becomes an AI-native healthcare platform.

The macro regime breaks hospital capital budgets. Extended 6%+ rates permanently freeze new Mako placements. Concurrently, GLP-1 therapies and preventative biologics physically shrink the incidence rate of osteoarthritis.

• Revenue growth decelerates to low-single digits.
• Supply chain inflation structurally compresses gross margins.
• The 37x P/E multiple collapses to a mid-teens hardware multiple.
• Equity value suffers severe, sustained compression as the 'growth compounder' narrative dies.

The crowd views Stryker as a high-quality, steady-growth defensive compounder. Wall Street focuses entirely on trailing earnings, hospital budget surveys, and quarterly consumable pull-through. They accept the 37x P/E multiple as a fair premium for demographic certainty and predictable mid-single-digit margin expansion. The narrative is utterly conventional: 'Aging boomers need knees, Stryker makes the best knees, buy the stock.' They view Mako as an evolutionary tool, completely missing the underlying platform physics.

The market is fundamentally mispricing the nature of Stryker's moat. The crowd prices Stryker as a physical titanium manufacturer with a side-hustle in robotics. The variant perception is that Stryker is building a proprietary, closed-loop data engine. By controlling the preoperative imaging, the intraoperative kinematics, and the postoperative outcomes, Stryker is training specialized AI models that no software startup can ever replicate because they lack physical access to the operating room. Stryker is not selling hardware; it is selling the Operating System for human surgery.

The tipping point occurs when Stryker formally launches a software-as-a-service (SaaS) or AI-monetization tier natively integrated into the Mako platform, demonstrating explicitly that surgical data and autonomous efficiency yield pure software margins. Expect this within 18-24 months as the frontier AI S-curve collides with their installed base.